Compare WGO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | CGEM |
|---|---|---|
| Founded | 1958 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.1M | 904.7M |
| IPO Year | 1994 | 2020 |
| Metric | WGO | CGEM |
|---|---|---|
| Price | $28.67 | $15.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $42.78 | $30.13 |
| AVG Volume (30 Days) | 657.9K | ★ 1.2M |
| Earning Date | 03-25-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 106.82 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,985,674,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.69 | $5.20 |
| P/E Ratio | $79.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.29 | $5.68 |
| 52 Week High | $50.16 | $16.74 |
| Indicator | WGO | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 55.66 |
| Support Level | $27.47 | $11.87 |
| Resistance Level | $35.01 | $16.31 |
| Average True Range (ATR) | 1.11 | 1.19 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 44.09 | 68.12 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.